BioSim™ anti-Ipilimumab (Yervoy®) (Human) ELISA Kit
- Usually Shipped in 5 Working Days
- 100 Assays
- Storage Conditions:
- Shipping Conditions:
- Gel Pack
- Shelf life:
- 12 months
Ipilimumab (Yervoy®) is a fully human IgG1κ antibody that binds to CTLA-4 (cytotoxic T lymphocyteassociated antigen 4), a molecule on T-cells that is indicated for unresectable or metastatic melanoma. The absence or presence of CTLA-4 can augment or suppress the immune system's T-cell response in fighting disease. Ipilimumab is designed to block the activity of CTLA-4, thereby sustaining an active immune response in its attack on cancer cells. The proposed mechanism of action is indirect, and may be through T-cell - mediated anti-tumor immune responses. However, some patients develop unwanted immunogenicity, which leads to production of anti-drug-antibodies (ADAs) inactivating the therapeutic effects of the treatment and, in rare cases, inducing adverse effects. BioVision’s BioSimTM anti-Ipilimumab ELISA kit is designed to detect antibody against Ipilimumab with high specificity and sensitivity in biological matrices.
Alternate Name: N/A
Tag Line: A Sandwich ELISA kit for the qualitative determination of antibody against Ipilimumab (Yervoy) in human serum or plasma.
Summary: • Detection method- Absorbance (450 nm) • Species reactivity- Human • Application- qualitative determination of antibody against Ipilimumab (Yervoy) in human serum and plasma
Detection Method: Absorbance (450 nm)
Sample Type: Human serum and plasma
Species Reactivity: Human
Applications: This ELISA kit is used for Qualitative determination of antibody against Ipilimumab (Yervoy) in serum and plasma
Features & Benefits: Easy, convenient, sensitive and time-saving method toqualitative determination of antibody against Ipilimumab (Yervoy) in human serum and plasma. Cross Reactivity: Ipilimumab (Yervoy®) infusion camouflages/masks the presence of antibody to Ipilimumab (ATP) in serum/plasma samples. Therefore, blood sampling time is critical for detection of ATP. It is convenient to obtain blood sample just before the infusion or at least 2 weeks after the infusion of Ipilimumab.